These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 31777490)

  • 1. Effect of oral eplerenone in anatomical and functional improvement in patients with chronic central serous chorioretinopathy.
    Farooq O; Habib A; Shah MA; Ahmed N
    Pak J Med Sci; 2019; 35(6):1544-1547. PubMed ID: 31777490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral Mineralocorticoid-Receptor Antagonists: Choroidal Parameters Changes Using OCT in Central Serous Chorioretinopathy.
    Faghihi H; Mohammadzadeh V; Nabavi A; Faghihi S; Kadivar S; Ghassemi F
    Ophthalmic Surg Lasers Imaging Retina; 2019 Nov; 50(11):726-733. PubMed ID: 31755972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral eplerenone for the management of chronic central serous chorioretinopathy.
    Singh RP; Sears JE; Bedi R; Schachat AP; Ehlers JP; Kaiser PK
    Int J Ophthalmol; 2015; 8(2):310-4. PubMed ID: 25938046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Routine Clinical Practice Treatment Outcomes of Eplerenone in Acute and Chronic Central Serous Chorioretinopathy.
    Fasler K; Gunzinger JM; Barthelmes D; Zweifel SA
    Front Pharmacol; 2021; 12():675295. PubMed ID: 34040534
    [No Abstract]   [Full Text] [Related]  

  • 5. [Eplerenone treatment in chronic central serous chorioretinopathy].
    Sampo M; Soler V; Gascon P; Ho Wang Yin G; Hoffart L; Denis D; Matonti F
    J Fr Ophtalmol; 2016 Jun; 39(6):535-42. PubMed ID: 27230892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eplerenone Treatment in Chronic Central Serous Chorioretinopathy.
    Iqbal F; Iqbal K; Inayat B; Arjumand S; Ghafoor Z; Sattar W; Abbas K
    Cureus; 2021 Oct; 13(10):e18415. PubMed ID: 34729255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eplerenone for the treatment of chronic central serous chorioretinopathy: 3-year clinical experience.
    Petkovsek DS; Cherfan DG; Conti FF; Hom GL; Ehlers JP; Babiuch AS; Rachitskaya AV; Kaiser PK; Schachat AP; Srivastava SK; Sharma S; Singh RP
    Br J Ophthalmol; 2020 Feb; 104(2):182-187. PubMed ID: 31079056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of Outcome During Eplerenone Therapy in Chronic Central Serous Chorioretinopathy:A Prospective, Open-Label Pilot Clinical Study.
    Rajesh B; Agrawal H; Peguda HK; Chhablani J
    Ophthalmic Surg Lasers Imaging Retina; 2018 Jul; 49(7):479-486. PubMed ID: 30021034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effect of Eplerenone in Chronic Central Serous Chorioretinopathy Refractory to Photodynamic Therapy.
    Karagiannis D; Parikakis E; Kontomichos L; Batsos G; Chatziralli I
    Semin Ophthalmol; 2019; 34(6):436-441. PubMed ID: 31309849
    [No Abstract]   [Full Text] [Related]  

  • 10. Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial.
    Lotery A; Sivaprasad S; O'Connell A; Harris RA; Culliford L; Ellis L; Cree A; Madhusudhan S; Behar-Cohen F; Chakravarthy U; Peto T; Rogers CA; Reeves BC;
    Lancet; 2020 Jan; 395(10220):294-303. PubMed ID: 31982075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term eplerenone for treatment of chronic central serous chorioretinopathy; a prospective study.
    Moein HR; Bierman LW; Novais EA; Moreira-Neto C; Baumal CR; Rogers A; Duker JS; Witkin AJ
    Int J Retina Vitreous; 2019; 5():39. PubMed ID: 31516734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optical Coherence Tomography Parameters as Predictors of Treatment Response to Eplerenone in Central Serous Chorioretinopathy.
    Borrelli E; Zuccaro B; Zucchiatti I; Parravano M; Querques L; Costanzo E; Sacconi R; Prascina F; Scarinci F; Bandello F; Querques G
    J Clin Med; 2019 Aug; 8(9):. PubMed ID: 31443376
    [No Abstract]   [Full Text] [Related]  

  • 13. Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study.
    Schwartz R; Habot-Wilner Z; Martinez MR; Nutman A; Goldenberg D; Cohen S; Shulman S; Guzner-Gur H; Loewenstein A; Goldstein M
    Acta Ophthalmol; 2017 Nov; 95(7):e610-e618. PubMed ID: 28653813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical experience with eplerenone to treat chronic central serous chorioretinopathy.
    Cakir B; Fischer F; Ehlken C; Bühler A; Stahl A; Schlunck G; Böhringer D; Agostini H; Lange C
    Graefes Arch Clin Exp Ophthalmol; 2016 Nov; 254(11):2151-2157. PubMed ID: 27145785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral Eplerenone Versus Observation in the Management of Acute Central Serous Chorioretinopathy: A Prospective, Randomized Comparative Study.
    Venkatesh R; Pereira A; Jayadev C; Prabhu V; Aseem A; Jain K; Bavaharan B; Yadav NK; Chhablani J
    Pharmaceuticals (Basel); 2020 Jul; 13(8):. PubMed ID: 32751370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy.
    Pichi F; Carrai P; Ciardella A; Behar-Cohen F; Nucci P;
    Int Ophthalmol; 2017 Oct; 37(5):1115-1125. PubMed ID: 27757733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mineralocorticoid Receptor Antagonists in Central Serous Chorioretinopathy: A Meta-Analysis of Randomized Controlled Trials.
    Wang SK; Sun P; Tandias RM; Seto BK; Arroyo JG
    Ophthalmol Retina; 2019 Feb; 3(2):154-160. PubMed ID: 31014765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minoxidil induced central serous Chorioretinopathy treated with oral Eplerenone - a case report.
    Venkatesh R; Pereira A; Jain K; Yadav NK
    BMC Ophthalmol; 2020 Jun; 20(1):219. PubMed ID: 32503484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anatomical and Functional Changes of the Retina and the Choroid after Resolved Chronic CSCR.
    Toto L; D'Aloisio R; Mastropasqua R; Di Antonio L; Di Nicola M; Di Martino G; Evangelista F; Erroi E; Doronzo E; Mariotti C
    J Clin Med; 2019 Apr; 8(4):. PubMed ID: 30959979
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.